Notice: Our website will be down for maintenance from June 13 - June 14.

Shire Discontinues Hemophilia Gene Therapy Drug Development

The following is an excerpt from To read the article in full, click here.On a conference call Tuesday, Shire CEO Flemming Ornskov said that the Dublin and Lexington, MA, company has discontinued development of BAX 335, an experimental gene therapy for hemophilia B. Prior to the merger of Baxalta and Shire, Baxalta had indicated plans to […]